Clinical trialNCT03828019CompletedPhase 3Interventional

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

SponsorJHSPH Center for Clinical TrialsEnrollment227Uveitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-tumor necrosis(TNF)-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Douglas A Jabs, MD MBA
CCTand Evidence Synthesis, JHU, Bloomberg School of Public Health
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Centre for Eye Research Australia
East Melbourne, Victoria, Australia
University of Sydney
Sydney, Australia

United Kingdom

University Hospital Birmingham
Edgbaston, Birmingham, United Kingdom
Bradford Teaching Hospital Nhs Foundation Trust
Bradford, United Kingdom
Cambridge University Nhs Trust
Cambridge, United Kingdom
University Hospitals of Leicester
Leicester, United Kingdom
Moorfields Eye Hospital Nhs Foundation Trust
London, United Kingdom

United States

Jules Stein Eye Institute, Ucla
Los Angeles, California, United States
University of California, San Francisco
San Francisco, California, United States
Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
Johns Hopkins University
Baltimore, Maryland, United States
National Eye Institute
Bethesda, Maryland, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
University of Michigan Health System, Kellogg Eye Center
Ann Arbor, Michigan, United States
Washington University
St Louis, Missouri, United States
Midatlantic Retina, Wills Eye Hospital
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Tennessee Retina
Nashville, Tennessee, United States
Vanderbilt University Eye Institute
Nashville, Tennessee, United States
Retinal Consultants of Texas
Bellaire, Texas, United States
University of Utah, Moran Eye Center
Salt Lake City, Utah, United States
University of Washington, Medicine Eye Institute
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Adalimumab →Conventional immunosuppression

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Sept 2019
Primary completion: 2 Apr 2024
Completion: 9 Sept 2024
Last update posted: 16 May 2025
Registered enrollment: 227
Registry id: NCT03828019

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.